Real-world clinical experience of Xultophy in the management of patients with type 2 diabetes in a secondary care clinic

There were significant reductions in HbA1c and statistically insignificant weight gain over 12 months. Switching from GLP-1 analogues to Xultophy was associated with a greater HbA1c reduction compared to switching from insulin.